title: Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma.
abstract: Gene expression profiling has been used to divide diffuse large B-cell lymphoma into distinct molecular subtypes with different outcomes following immunochemotherapy. Recently, researchers have shown much interest in investigating the role of biomarkers, such as BCL2, in predicting outcome in diffuse large B-cell lymphoma, particularly in the context of these molecular subtypes.
authors.affiliation: National Cancer Institute, Bethesda, MD 20892, USA. dunleavk@mail.nih.gov
authors.forename: Kieron
authors.initials: K
authors.lastname: Dunleavy
authors.forename: Wyndham H
authors.initials: WH
authors.lastname: Wilson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2